BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hennrich U, Benešová M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel) 2020;13:E38. [PMID: 32138377 DOI: 10.3390/ph13030038] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 23.5] [Reference Citation Analysis]
Number Citing Articles
1 D'souza JC, O'brien SR, Yang Z, El Jack AK, Pantel AR. Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [68Ga]DOTATATE PET/CT. Radiology Case Reports 2023;18:481-485. [DOI: 10.1016/j.radcr.2022.10.059] [Reference Citation Analysis]
2 Patterson KN, Trout AT, Shenoy A, Abu-el-haija M, Nathan JD. Solid pancreatic masses in children: A review of current evidence and clinical challenges. Front Pediatr 2022;10. [DOI: 10.3389/fped.2022.966943] [Reference Citation Analysis]
3 Cieslik P, Kubeil M, Zarschler K, Ullrich M, Brandt F, Anger K, Wadepohl H, Kopka K, Bachmann M, Pietzsch J, Stephan H, Comba P. Toward Personalized Medicine: One Chelator for Imaging and Therapy with Lutetium-177 and Actinium-225. J Am Chem Soc 2022. [DOI: 10.1021/jacs.2c08438] [Reference Citation Analysis]
4 Riveira-martin M, Struelens L, Schoonjans W, Sánchez-díaz I, Muñoz Iglesias J, Ferreira Dávila Ó, Salvador Gómez FJ, Salgado Fernández M, López Medina A. Occupational radiation exposure assessment during the management of [68Ga]Ga-DOTA-TOC. EJNMMI Phys 2022;9:75. [DOI: 10.1186/s40658-022-00505-8] [Reference Citation Analysis]
5 Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals 2022;15:1292. [DOI: 10.3390/ph15101292] [Reference Citation Analysis]
6 Carrese B, Sanità G, Lamberti A. Nanoparticles Design for Theranostic Approach in Cancer Disease. Cancers 2022;14:4654. [DOI: 10.3390/cancers14194654] [Reference Citation Analysis]
7 Sun J, Huangfu Z, Yang J, Wang G, Hu K, Gao M, Zhong Z. Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation. Adv Drug Deliv Rev 2022;:114538. [PMID: 36162696 DOI: 10.1016/j.addr.2022.114538] [Reference Citation Analysis]
8 Califaretti E, Dall’armellina S, Rovera G, Finessi M, Deandreis D. The role of PET/CT in thyroid autoimmune diseases. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03464-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hirata S, Mishiro K, Higashi T, Fuchigami T, Munekane M, Arano Y, Kinuya S, Ogawa K. Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.08.004] [Reference Citation Analysis]
10 Ilhan H, Schnitzer ML, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Radiopraxis 2022;15:E35-E47. [DOI: 10.1055/a-1714-2040] [Reference Citation Analysis]
11 Desai P, Rimal R, Sahnoun SEM, Mottaghy FM, Möller M, Morgenroth A, Singh S. Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers. Small. [DOI: 10.1002/smll.202200673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol 2022; 28(17): 1768-1780 [DOI: 10.3748/wjg.v28.i17.1768] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers (Basel) 2022;14:2103. [PMID: 35565232 DOI: 10.3390/cancers14092103] [Reference Citation Analysis]
14 Hörmann AA, Plhak E, Klingler M, Rangger C, Pfister J, Schwach G, Kvaternik H, von Guggenberg E. Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting. Molecules 2022;27:2034. [PMID: 35335396 DOI: 10.3390/molecules27062034] [Reference Citation Analysis]
15 Tomita S, Higashikawa K, Mizuno Y, Tada T, Tazawa S, Kuge Y. Long-Term Radiation Safety Evaluation of <sup>68</sup>Ge/<sup>68</sup>Ga Generator. RADIOISOTOPES 2022;71:1-8. [DOI: 10.3769/radioisotopes.71.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Virarkar M, Gopireddy DR, Morani AC, Alkhasawneh A, Klimkowski SP, Kumar S, Lall C, Bhosale P. Rectal neuroendocrine neoplasms: what the radiologists should know. Abdom Radiol (NY) 2022. [PMID: 35288791 DOI: 10.1007/s00261-022-03474-9] [Reference Citation Analysis]
17 Ilhan H, Schnitzer M, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Onkologie up2date 2022;04:93-106. [DOI: 10.1055/a-1712-0674] [Reference Citation Analysis]
18 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lepareur N. Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals? Front Med 2022;9:812050. [DOI: 10.3389/fmed.2022.812050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Sugo Y, Miyachi R, Obata S, Maruyama YH, Manabe H, Mori M, Ishioka NS, Toda K, Ohira SI. Rapid Flow-Based System for Separation of Radioactive Metals by Selective Complex Formation. Anal Chem 2021;93:17069-75. [PMID: 34910462 DOI: 10.1021/acs.analchem.1c03866] [Reference Citation Analysis]
21 Effendi N, Mishiro K, Wakabayashi H, Gabryel-Skrodzka M, Shiba K, Taki J, Jastrząb R, Kinuya S, Ogawa K. Synthesis and evaluation of radiogallium-labeled long-chain fatty acid derivatives as myocardial metabolic imaging agents. PLoS One 2021;16:e0261226. [PMID: 34910775 DOI: 10.1371/journal.pone.0261226] [Reference Citation Analysis]
22 Lee K, Ahn B, Hong SM, Ahn JY, Gong CS, Ryu JS. A Case of Glomus Tumor Mimicking Neuroendocrine Tumor on 68 Ga-DOTATOC PET/CT. Nucl Med Mol Imaging 2021;55:315-9. [PMID: 34868381 DOI: 10.1007/s13139-021-00717-3] [Reference Citation Analysis]
23 Ilhan H, Schnitzer ML, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Der Nuklearmediziner 2021;44:313-325. [DOI: 10.1055/a-1652-4899] [Reference Citation Analysis]
24 Oh D, Choi H, Paeng JC, Kang KW, Cheon GJ. A Negative Correlation Between Blood Glucose Level and 68 Ga-DOTA-TOC Uptake in the Pancreas Uncinate Process. Nucl Med Mol Imaging 2022;56:52-8. [DOI: 10.1007/s13139-021-00723-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Choiński J, Łyczko M. Prospects for the production of radioisotopes and radiobioconjugates for theranostics. Bio-Algorithms and Med-Systems 2022;17:241-57. [DOI: 10.1515/bams-2021-0136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
26 Svedjehed J, Pärnaste M, Gagnon K. Demystifying solid targets: Simple and rapid distribution-scale production of [68Ga]GaCl3 and [68Ga]Ga-PSMA-11. Nucl Med Biol 2021;104-105:1-10. [PMID: 34763197 DOI: 10.1016/j.nucmedbio.2021.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
27 Spears RJ, McMahon C, Chudasama V. Cysteine protecting groups: applications in peptide and protein science. Chem Soc Rev 2021;50:11098-155. [PMID: 34605832 DOI: 10.1039/d1cs00271f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
28 Foster A, Nigam S, Tatum DS, Raphael I, Xu J, Kumar R, Plakseychuk E, Latoche JD, Vincze S, Li B, Giri R, McCarl LH, Edinger R, Ak M, Peddagangireddy V, Foley LM, Hitchens TK, Colen RR, Pollack IF, Panigrahy A, Magda D, Anderson CJ, Edwards WB, Kohanbash G. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. EBioMedicine 2021;71:103571. [PMID: 34530385 DOI: 10.1016/j.ebiom.2021.103571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
29 George KJH, Borjian S, Cross MC, Hicks JW, Schaffer P, Kovacs MS. Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons. RSC Adv 2021;11:31098-123. [PMID: 35498914 DOI: 10.1039/d1ra04480j] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci 2021:S0165-6147(21)00136-X. [PMID: 34334251 DOI: 10.1016/j.tips.2021.07.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
31 Chastel A, Vimont D, Claverol S, Zerna M, Bodin S, Berndt M, Chaignepain S, Hindié E, Morgat C. 68Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [68Ga]Ga-RM2. Pharmaceutics 2021;13:1160. [PMID: 34452121 DOI: 10.3390/pharmaceutics13081160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chigoho DM, Bridoux J, Hernot S. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals. Curr Opin Chem Biol 2021;63:219-28. [PMID: 34325089 DOI: 10.1016/j.cbpa.2021.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
33 Gower-Fry L, Kronemann T, Dorian A, Pu Y, Jaworski C, Wängler C, Bartenstein P, Beyer L, Lindner S, Jurkschat K, Wängler B, Bailey JJ, Schirrmacher R. Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals. Pharmaceuticals (Basel) 2021;14:701. [PMID: 34358127 DOI: 10.3390/ph14070701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wongso H. Natural product-based Radiopharmaceuticals:Focus on curcumin and its analogs, flavonoids, and marine peptides. Journal of Pharmaceutical Analysis 2021. [DOI: 10.1016/j.jpha.2021.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Wu P, Siegwart DJ, Xiong H. Recent advances in the targeted fluorescent probes for the detection of metastatic bone cancer. Sci China Chem 2021;64:1283-96. [DOI: 10.1007/s11426-021-9990-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Grieve ML, Davey PRWJ, Forsyth CM, Paterson BM. The Synthesis of a Bis(thiosemicarbazone) Macrocyclic Ligand and the Mn(II), Co(II), Zn(II) and 68Ga(III) Complexes. Molecules 2021;26:3646. [PMID: 34203751 DOI: 10.3390/molecules26123646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Sheikhbahaei S, Sadaghiani MS, Rowe SP, Solnes LB. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. AJR Am J Roentgenol 2021;217:495-506. [PMID: 34076455 DOI: 10.2214/AJR.20.23349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E. Theranostic Advances in Breast Cancer in Nuclear Medicine. Int J Mol Sci 2021;22:4597. [PMID: 33925632 DOI: 10.3390/ijms22094597] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
39 Liang X, Wu P, Yang Q, Xie Y, He C, Yin L, Yin Z, Yue G, Zou Y, Li L, Song X, Lv C, Zhang W, Jing B. An update of new small-molecule anticancer drugs approved from 2015 to 2020. Eur J Med Chem 2021;220:113473. [PMID: 33906047 DOI: 10.1016/j.ejmech.2021.113473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
40 Garnier H, Loo C, Czauderna P, Vasudevan SA. Pediatric Gastrointestinal Stromal Tumors and Neuroendocrine Tumors: Advances in Surgical Management. Surg Oncol Clin N Am 2021;30:219-33. [PMID: 33706897 DOI: 10.1016/j.soc.2020.11.001] [Reference Citation Analysis]
41 Herrero Álvarez N, Bauer D, Hernández-Gil J, Lewis JS. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021. [PMID: 33792195 DOI: 10.1002/cmdc.202100135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
42 Pérez DJ, Ávila-rodríguez MA. Methods to radiolabel somatostatin analogs with [18F]fluoride: current status, challenges, and progress in clinical applications. J Radioanal Nucl Chem 2020;326:1519-1542. [DOI: 10.1007/s10967-020-07437-6] [Reference Citation Analysis]
43 Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology 2021;298:261-74. [PMID: 33231532 DOI: 10.1148/radiol.2020201745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
44 Redfern JS. Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands. PPIJ 2020;8:325-331. [DOI: 10.15406/ppij.2020.08.00313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Mukai H, Watanabe Y. Review: PET imaging with macro- and middle-sized molecular probes. Nucl Med Biol 2021;92:156-70. [PMID: 32660789 DOI: 10.1016/j.nucmedbio.2020.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
46 Harris AG, Vinik AI, OʼDorisio TM, OʼDorisio MS. Radioligand Theranostics in the Management of Neuroendocrine Tumors. Pancreas 2020;49:599-603. [PMID: 32433395 DOI: 10.1097/MPA.0000000000001546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]